• Financial momentum for Nutriband is indicated by its recent Q1 financial report
• Progress continues development of proprietary AVERSA(TM) Fentanyl, notes quarterly report
• AVERSA(TM) Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch

A wave of positive developments continues to build momentum for Nutriband (NASDAQ: NTRB), with recent capital funding, strategic partnerships and an expanded intellectual property portfolio reinforcing its bid to lead in the development of safer transdermal therapies. Nutriband is positioning itself at the forefront of abuse-deterrent drug delivery by advancing its Aversa platforms, notably its flagship fentanyl patch and buprenorphine candidates.

Financial momentum for Nutriband is indicated by its recent Q1 financial report (ibn.fm/8R0ca), which noted that the company posted record Q1 2025 revenue of $667,000 — a 63% year-over-year increase — driven by expansion in its kinesiology tape manufacturing via subsidiary Pocono Pharma and growing retail sales at Target, Walmart, Walgreens and CVS.

The company also reported that it is continuing to expand its kinesiology tape output through its Pocono Pharma subsidiary, with a continued focus on penetration pricing to gain a foothold with some of the industry’s largest brands. “Progress continues on the development of AVERSA Fentanyl, with the company formalizing an exclusive product development partnership with Kindeva Drug Delivery,” the report stated. “The formalized partnership with Kindeva Drug Delivery reflects a commitment to shared development costs in exchange for milestone payments, enabling Nutriband to advance its innovative transdermal drug-delivery solutions towards regulatory approval and commercialization.”

The company’s momentum began last year with a notable milestone: the closing of an $8.4 million private placement earmarked to fund AVERSA(TM) Fentanyl’s full-scale commercial development ahead of an expected 2025 NDA submission (ibn.fm/9SZ8B). The company is working with Kindeva, an FDA-approved contract development and manufacturing organization (“CDMO”), to integrate its transdermal abuse-deterrent technology into Kindeva’s existing fentanyl patch. The goal is a best-in-class 505(b)(2) application supported by a single phase 1 human abuse-potential study, bypassing the usual phase 2 and 3 trials.

“AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches,” the company stated. “AVERSA(TM) Fentanyl has the potential to reach peak annual U.S. sales of $80 million to $200 million.”

Alongside fentanyl, Nutriband is advancing AVERSA(TM) Buprenorphine, projected to achieve peak U.S. sales between $70 million and $130 million upon approval (https://ibn.fm/mIHdw). Like its counterpart, AVERSA Buprenorphine benefits from Nutriband’s scalable abuse-deterrent platform, and the technology is being positioned for global patent protection.

Nutriband’s forward trajectory is clear: combining transdermal innovation with abuse-deterrent science to meet critical public health needs. With its commercial infrastructure and pipeline expansion, the company is paving a path toward safer opioid management. As the opioid crisis continues, Nutriband’s leadership in transdermal patch technology offers a promising model for improving patient safety without sacrificing efficacy.

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN